{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Repros+Therapeutics+Inc.", "query": { "sponsor": "Repros Therapeutics Inc." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Repros+Therapeutics+Inc.&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T12:23:37.839Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00882258", "title": "Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Fibroids" ], "interventions": [ { "name": "12.5 mg Proellex", "type": "DRUG" }, { "name": "25 mg Proellex", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 144, "start_date": "2006-03", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2014-07-08", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882258" }, { "nct_id": "NCT01993225", "title": "A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Secondary Hypogonadism" ], "interventions": [ { "name": "Androxal 12.5 mg/25 mg", "type": "DRUG" }, { "name": "Placebo Capsules", "type": "DRUG" }, { "name": "AndroGel 1.62%", "type": "DRUG" }, { "name": "Placebo Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 120, "start_date": "2014-01", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-10-01", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Garden City", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01993225" }, { "nct_id": "NCT01631903", "title": "Extension of Study ZPV-200", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Fibroids" ], "interventions": [ { "name": "telepristone acetate 12 mg", "type": "DRUG" }, { "name": "telepristone acetate 3 mg", "type": "DRUG" }, { "name": "telepristone acetate 6 mg", "type": "DRUG" }, { "name": "telepristone acetate 24 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "47 Years", "sex": "FEMALE", "summary": "18 Years to 47 Years · Female only" }, "enrollment_count": 48, "start_date": "2012-09", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-04-16", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 2, "location_summary": "Miami Gardens, Florida • Houston, Texas", "locations": [ { "city": "Miami Gardens", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01631903" }, { "nct_id": "NCT02323646", "title": "Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Fibroids" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Telapristone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "47 Years", "sex": "FEMALE", "summary": "18 Years to 47 Years · Female only" }, "enrollment_count": 42, "start_date": "2015-02-12", "completion_date": "2017-04-06", "has_results": true, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 8, "location_summary": "Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Saginaw", "state": "Michigan" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323646" }, { "nct_id": "NCT01962805", "title": "Comparison of Two Formulations of Proellex for Vaginal Administration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules" ], "interventions": [ { "name": "Proellex Formulation A", "type": "DRUG" }, { "name": "Proellex Formulation B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "47 Years", "sex": "FEMALE", "summary": "18 Years to 47 Years · Female only" }, "enrollment_count": 8, "start_date": "2013-10", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-01-24", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962805" }, { "nct_id": "NCT02811159", "title": "An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Fibroids" ], "interventions": [ { "name": "Telapristone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "47 Years", "sex": "FEMALE", "summary": "18 Years to 47 Years · Female only" }, "enrollment_count": 20, "start_date": "2016-07-26", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 8, "location_summary": "Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Jackson", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02811159" }, { "nct_id": "NCT01984398", "title": "Comparison of Two Formulations of Androxal", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bioequivalence" ], "interventions": [ { "name": "12.5 mg Androxal Formulation A", "type": "DRUG" }, { "name": "12.5 mg Androxal Formulation B", "type": "DRUG" }, { "name": "25 mg Androxal Formulation A", "type": "DRUG" }, { "name": "25 mg Androxal Formulation B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 16, "start_date": "2013-12-31", "completion_date": "2013-12-31", "has_results": true, "last_update_posted_date": "2019-05-06", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984398" }, { "nct_id": "NCT01728454", "title": "Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Telapristone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "47 Years", "sex": "FEMALE", "summary": "18 Years to 47 Years · Female only" }, "enrollment_count": 60, "start_date": "2013-05-02", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 10, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01728454" }, { "nct_id": "NCT01534208", "title": "Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Secondary Hypogonadism" ], "interventions": [ { "name": "Androxal", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 499, "start_date": "2012-05", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 31, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chino", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534208" }, { "nct_id": "NCT01923870", "title": "Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Secondary Hypogonadism" ], "interventions": [ { "name": "Androxal 25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "18 Years to 70 Years · Male only" }, "enrollment_count": 19, "start_date": "2013-08", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-01-24", "last_synced_at": "2026-10-02T12:23:37.839Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01923870" } ] }